TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Intercure ( (IL:INCR) ).
InterCure Ltd. announced the strategic acquisition of Botanico Ltd., also known as ISHI, on September 17, 2025. This acquisition, expected to close in Q1 2026, marks a significant milestone in InterCure’s global expansion strategy by providing access to premium U.S. cannabis technology and brands. The transaction involves acquiring 100% of ISHI in two phases, with the initial phase involving the purchase of 50% of ISHI’s shares. This move positions InterCure to capitalize on potential regulatory changes in the U.S. cannabis market, particularly the rescheduling of cannabis, which could open new opportunities for international operators. The acquisition also strengthens InterCure’s management team with the inclusion of ISHI’s founders and enhances its supply chain and distribution operations.
The most recent analyst rating on (IL:INCR) stock is a Hold with a ILs548.00 price target. To see the full list of analyst forecasts on Intercure stock, see the IL:INCR Stock Forecast page.
More about Intercure
InterCure Ltd., operating as Canndoc, is a leading and rapidly growing cannabis company outside North America. It is Israel’s largest licensed cannabis producer, known for offering GMP-certified and pharmaceutical-grade medical cannabis products. InterCure utilizes a vertically integrated ‘seed-to-sale’ model and has a strong distribution network and international partnerships, positioning it as a leader in the global cannabis market.
Average Trading Volume: 52,577
Technical Sentiment Signal: Strong Sell
Current Market Cap: ILs280.6M
See more insights into INCR stock on TipRanks’ Stock Analysis page.